Stockreport

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen, Inc.  (OCGN) 
PDF Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date Eur [Read more]